• A novel activating JAK1 mutation in chronic eosinophilic leukemia.

  Shomali W, Damnernsawad A, Theparee T, Sampson D, Morrow Q, Yang F, Fernandez-Pol S, Press R, Zehnder J, Tyner JW, Gotlib J.
  Blood Adv. 2021 Sep 28. 18(5).

• Spatially organized multicellular immune hubs in human colorectal cancer.

  Pelka K, Hofree M, Chen JH, Sarkizova S, Pirl JD, Jorgji V, Bejnood A, Dionne D, Ge WH, Xu KH, Chao SX, Zollinger DR, Lieb DJ, Reeves JW, Fuhrman CA, Hoang ML, Delorey T, Nguyen LT, Waldman J, Klapholz M, Wakiro I, Cohen O, Albers J, Smillie CS, Cuoco MS, Wu J, Su MJ, Yeung J, Vijaykumar B, Magnuson AM, Asinovski N, Moll T, Goder-Reiser MN, Applebaum AS, Brais LK, DelloStritto LK, Denning SL, Phillips ST, Hill EK, Meehan JK, Frederick DT, Sharova T, Kanodia A, Todres EZ, Jané-Valbuena J, Biton M, Izar B, Lambden CD, Clancy TE, Bleday R, Melnitchouk N, Irani J, Kunitake H, Berger DL, Srivastava A, Hornick JL, Ogino S, Rotem A, Vigneau S, Johnson BE, Corcoran RB, Sharpe AH, Kuchroo VK, Ng K, Giannakis M, Nieman LT, Boland GM, Aguirre AJ, Anderson AC, Rozenblatt-Rosen O, Regev A, Hacohen N.
  Cell. 2021 Sep 02. 18(184).

• BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program.

  Kim DH, Sun D, Storck WK, Welker Leng K, Jenkins C, Coleman DJ, Sampson D, Guan X, Kumaraswamy A, Rodansky ES, Urrutia JA, Schwartzman JA, Zhang C, Beltran H, Labrecque MP, Morrissey C, Lucas JM, Coleman IM, Nelson PS, Corey E, Handelman SK, Sexton JZ, Aggarwal R, Abida W, Feng FY, Small EJ, Spratt DE, Bankhead A, Rao A, Gesner EM, Attwell S, Lakhotia S, Campeau E, Yates JA, Xia Z, Alumkal JJ.
  Clin Cancer Res. 2021 Sep 01. 17(27).
  
  Data

• Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers.

  Mao N, Zhang Z, Lee YS, Choi D, Rivera AA, Li D, Lee C, Haywood S, Chen X, Chang Q, Xu G, Chen HA, de Stanchina E, Sawyers C, Rosen N, Hsieh AC, Chen Y, Carver BS.
  Nat Commun. 2021 Aug 20. 1(12).
  
  Data

• Rapid interrogation of cancer cell of origin through CRISPR editing.

  Feng W, Cao Z, Lim PX, Zhao H, Luo H, Mao N, Lee YS, Rivera AA, Choi D, Wu C, Han T, Romero R, de Stanchina E, Carver BS, Wang Q, Jasin M, Sawyers CL.
  Proc Natl Acad Sci U S A. 2021 Aug 10. 32(118).

• Exocyst protein subnetworks integrate Hippo and mTOR signaling to promote virus detection and cancer.

  Zaman A, Wu X, Lemoff A, Yadavalli S, Lee J, Wang C, Cooper J, McMillan EA, Yeaman C, Mirzaei H, White MA, Bivona TG.
  Cell Rep. 2021 Aug 03. 5(36).
  
  Data

• The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance.

  Joshi SK, Nechiporuk T, Bottomly D, Piehowski PD, Reisz JA, Pittsenbarger J, Kaempf A, Gosline SJC, Wang YT, Hansen JR, Gritsenko MA, Hutchinson C, Weitz KK, Moon J, Cendali F, Fillmore TL, Tsai CF, Schepmoes AA, Shi T, Arshad OA, McDermott JE, Babur O, Watanabe-Smith K, Demir E, D'Alessandro A, Liu T, Tognon CE, Tyner JW, McWeeney SK, Rodland KD, Druker BJ, Traer E.
  Cancer Cell. 2021 Jul 12. 7(39).
  
  Data Clinical Trial

• Stepwise evolution of therapy resistance in AML.

  Gui P, Bivona TG.
  Cancer Cell. 2021 Jul 12. 7(39).

• Multiplexed functional genomic analysis of 5' untranslated region mutations across the spectrum of prostate cancer.

  Lim Y, Arora S, Schuster SL, Corey L, Fitzgibbon M, Wladyka CL, Wu X, Coleman IM, Delrow JJ, Corey E, True LD, Nelson PS, Ha G, Hsieh AC.
  Nat Commun. 2021 Jul 09. 1(12).
  
  Data Model

• A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance.

  Joshi SK, Sharzehi S, Pittsenbarger J, Bottomly D, Tognon CE, McWeeney SK, Druker BJ, Traer E.
  Am J Hematol. 2021 Jul 01. 7(96).

• High-fat diet-activated fatty acid oxidation mediates intestinal stemness and tumorigenicity.

  Mana MD, Hussey AM, Tzouanas CN, Imada S, Barrera Millan Y, Bahceci D, Saiz DR, Webb AT, Lewis CA, Carmeliet P, Mihaylova MM, Shalek AK, Yilmaz ÖH.
  Cell Rep. 2021 Jun 08. 10(35).

• A CRISPR/Cas9-Engineered ARID1A-Deficient Human Gastric Cancer Organoid Model Reveals Essential and Nonessential Modes of Oncogenic Transformation.

  Lo YH, Kolahi KS, Du Y, Chang CY, Krokhotin A, Nair A, Sobba WD, Karlsson K, Jones SJ, Longacre TA, Mah AT, Tercan B, Sockell A, Xu H, Seoane JA, Chen J, Shmulevich I, Weissman JS, Curtis C, Califano A, Fu H, Crabtree GR, Kuo CJ.
  Cancer Discov. 2021 Jun. 6(11).
  
  Data Model

• Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment.

  Kerr DL, Haderk F, Bivona TG.
  Curr Opin Chem Biol. 2021 Jun. (62).

• Nanoparticle-enabled innate immune stimulation activates endogenous tumor-infiltrating T cells with broad antigen specificities.

  Yin Q, Yu W, Grzeskowiak CL, Li J, Huang H, Guo J, Chen L, Wang F, Zhao F, von Boehmer L, Metzner TJ, Leppert JT, Chien YH, Kuo CJ, Davis MM.
  Proc Natl Acad Sci U S A. 2021 May 25. 21(118).

• Kinase-mediated RAS signaling via membraneless cytoplasmic protein granules.

  Tulpule A, Guan J, Neel DS, Allegakoen HR, Lin YP, Brown D, Chou YT, Heslin A, Chatterjee N, Perati S, Menon S, Nguyen TA, Debnath J, Ramirez AD, Shi X, Yang B, Feng S, Makhija S, Huang B, Bivona TG.
  Cell. 2021 May 13. 10(184).

• Spatial decoding of endosomal cAMP signals by a metastable cytoplasmic PKA network.

  Peng GE, Pessino V, Huang B, von Zastrow M.
  Nat Chem Biol. 2021 May. 5(17).

• A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor.

  Dagogo-Jack I, Moonsamy P, Gainor JF, Lennerz JK, Piotrowska Z, Lin JJ, Lennes IT, Sequist LV, Shaw AT, Goodwin K, Stevens SE, Do A, Digumarthy SR, Price K, Muzikansky A, Hata AN, Heist RS.
  J Thorac Oncol. 2021 May. 5(16).
  
  Clinical Trial

• CRISPR-based functional genomics in human dendritic cells.

  Jost M, Jacobson AN, Hussmann JA, Cirolia G, Fischbach MA, Weissman JS.
  Elife. 2021 Apr 27. (10).

• Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling.

  Brady L, Kriner M, Coleman I, Morrissey C, Roudier M, True LD, Gulati R, Plymate SR, Zhou Z, Birditt B, Meredith R, Geiss G, Hoang M, Beechem J, Nelson PS.
  Nat Commun. 2021 Mar 03. 1(12).
  
  Data

• Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts.

  Quinn JJ, Jones MG, Okimoto RA, Nanjo S, Chan MM, Yosef N, Bivona TG, Weissman JS.
  Science. 2021 Feb 26. 6532(371).
  
  Data

• Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax.

  Moses BS, McCullough S, Fox JM, Mott BT, Bentzen SM, Kim M, Tyner JW, Lapidus RG, Emadi A, Rudek MA, Kingsbury TJ, Civin CI.
  Blood Adv. 2021 Feb 09. 3(5).

• CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment.

  Klomp JE, Lee YS, Goodwin CM, Papke B, Klomp JA, Waters AM, Stalnecker CA, DeLiberty JM, Drizyte-Miller K, Yang R, Diehl JN, Yin HH, Pierobon M, Baldelli E, Ryan MB, Li S, Peterson J, Smith AR, Neal JT, McCormick AK, Kuo CJ, Counter CM, Petricoin EF, Cox AD, Bryant KL, Der CJ.
  Cell Rep. 2021 Nov 30. 9(37).

• Pleiotropic Mechanisms Drive Endocrine Resistance in the Three-Dimensional Bone Microenvironment.

  Dhimolea E, de Matos Simoes R, Kansara D, Weng X, Sharma S, Awate P, Liu Z, Gao D, Mitsiades N, Schwab JH, Chen Y, Jeselsohn R, Culhane AC, Brown M, Georgakoudi I, Mitsiades CS.
  Cancer Res. 2021 Jan 15. 2(81).

• Modeling human adaptive immune responses with tonsil organoids.

  Wagar LE, Salahudeen A, Constantz CM, Wendel BS, Lyons MM, Mallajosyula V, Jatt LP, Adamska JZ, Blum LK, Gupta N, Jackson KJL, Yang F, Röltgen K, Roskin KM, Blaine KM, Meister KD, Ahmad IN, Cortese M, Dora EG, Tucker SN, Sperling AI, Jain A, Davies DH, Felgner PL, Hammer GB, Kim PS, Robinson WH, Boyd SD, Kuo CJ, Davis MM.
  Nat Med. 2021 Jan. 1(27).
  
  Data

• Cell-Free HPV DNA Provides an Accurate and Rapid Diagnosis of HPV-Associated Head and Neck Cancer.

  Siravegna G, O'Boyle CJ, Varmeh S, Queenan N, Michel A, Stein J, Thierauf J, Sadow PM, Faquin WC, Perry SK, Bard AZ, Wang W, Deschler DG, Emerick KS, Varvares MA, Park JC, Clark JR, Chan AW, Andreu Arasa VC, Sakai O, Lennerz J, Corcoran RB, Wirth LJ, Lin DT, Iafrate AJ, Richmon JD, Faden DL.
  Clin Cancer Res. 2021 Dec 02. ().

• FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma.

  Cleary JM, Raghavan S, Wu Q, Li YY, Spurr LF, Gupta HV, Rubinson DA, Fetter IJ, Hornick JL, Nowak JA, Siravegna G, Goyal L, Shi L, Brais LK, Loftus M, Shinagare AB, Abrams TA, Clancy TE, Wang J, Patel AK, Brichory F, Vaslin Chessex A, Sullivan RJ, Keller RB, Denning S, Hill ER, Shapiro GI, Pokorska-Bocci A, Zanna C, Ng K, Schrag D, Jänne PA, Hahn WC, Cherniack AD, Corcoran RB, Meyerson M, Daina A, Zoete V, Bardeesy N, Wolpin BM.
  Cancer Discov. 2021 Oct. 10(11).

• Monocytic differentiation and AHR signaling as Primary Nodes of BET Inhibitor Response in Acute Myeloid Leukemia.

  Romine KA, Nechiporuk T, Bottomly D, Jeng S, McWeeney SK, Kaempf A, Corces MR, Majeti R, Tyner JW.
  Blood Cancer Discov. 2021 Sep. 5(2).

• Clinical Acquired Resistance to KRAS^G12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation.

  Tanaka N, Lin JJ, Li C, Ryan MB, Zhang J, Kiedrowski LA, Michel AG, Syed MU, Fella KA, Sakhi M, Baiev I, Juric D, Gainor JF, Klempner SJ, Lennerz JK, Siravegna G, Bar-Peled L, Hata AN, Heist RS, Corcoran RB.
  Cancer Discov. 2021 Aug. 8(11).
  
  Clinical Trial

• The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches.

  Labrecque MP, Alumkal JJ, Coleman IM, Nelson PS, Morrissey C.
  Endocr Relat Cancer. 2021 Jul 15. 8(28).

• Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy.

  Meermeier EW, Welsh SJ, Sharik ME, Du MT, Garbitt VM, Riggs DL, Shi CX, Stein CK, Bergsagel M, Chau B, Wheeler ML, Bezman N, Wang F, Strop P, Bergsagel PL, Chesi M.
  Blood Cancer Discov. 2021 Jul. 4(2).
  
  Model

• DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia.

  Giacopelli B, Wang M, Cleary A, Wu YZ, Schultz AR, Schmutz M, Blachly JS, Eisfeld AK, Mundy-Bosse B, Vosberg S, Greif PA, Claus R, Bullinger L, Garzon R, Coombes KR, Bloomfield CD, Druker BJ, Tyner JW, Byrd JC, Oakes CC.
  Genome Res. 2021 May. 5(31).
  
  Data

• Ex Vivo Analysis of Primary Tumor Specimens for Evaluation of Cancer Therapeutics.

  Tognon CE, Sears RC, Mills GB, Gray JW, Tyner JW.
  Annu Rev Cancer Biol. 2021 Mar. (5).

• Outgrowth of a CSF3R-mutant clone drives a second myeloproliferative neoplasm in a chronic myeloid leukemia patient: a case report.

  Carratt SA, Brewer D, Maxson JE, Druker BJ, Braun TP.
  Biomark Res. 2021 Jan 30. 1(9).